Stock Ratings / Health Care / SRTA / dividends

AUNA (61) SBC (71) STLN (37) AHCO (45) ⌘ Pro Terminal →

Strata Critical Medical Inc. (Class A) (SRTA) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.75 -0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.74

Strata Critical Medical Inc. (Class A) (SRTA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $420.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.74 (-0.23%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRTA)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY SRTA SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (34% of score)

Altman Z-Score 5.58 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (21% of score)

FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.53+0.2% Next Q

Q2 (-2Q)

Grade D$4.54+2.6% Next Q

Q3 (-1Q)

Grade D$4.66+1.9% Next Q

Current

Grade D$4.75-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRTA currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.10) and Max Pain ($4.99) forces dealer call-delta covering toward $6.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRTA)

✓Walkthrough of SRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.38%▼ DESCENDING CHANNEL

2026-10-30O $4.70H $4.75L $4.40C $4.75VOL 1.11M

RES: $6.19SUP: $4.08SMA50: $5.10SMA200: $5.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRTA Butterfly Map → + Track SRTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-0.8%/yr Implied 5Y Growth

vs. +34.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRTA)

Health Care Rank #410 of 1016 ⚔️ AUNA vs SRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRTA vs. AUNA, SBC, STLN, AHCO)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Strata Critical Medical Inc. (Class A) (SRTA) ranks #410 by composite RQD confidence (47/100, grade D) and #474 by equity capitalization ($420.2M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with SRTA at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRTA ACTIVE Strata Critical Medical Inc. (Class A)	D	47/100	10.2x	20.9%	-7.1%	-0.21%	$420.2M	Benchmark Subject
AUNA Auna SA (Class A)	C-	61/100	—	—	—	+1.27%	$355.3M	/auna-vs-srta →
SBC SBC Medical Group Holdings Incorporated	B-	71/100	11.5x	73.3%	63.1%	+4.40%	$585.2M	/sbc-vs-srta →
STLN Starling Oncology Inc.	D-	37/100	—	—	-35.0%	+0.15%	$677.7M	/stln-vs-srta →
AHCO AdaptHealth Corp.	D	45/100	—	18.8%	2.2%	-1.66%	$808.5M	/ahco-vs-srta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779128

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Strata Critical Medical Inc. (Class A) (SRTA) reported GAAP revenue of $197.1M (+34.3% vs. FY2024 revenue of $146.8M , and -12.5% cumulative change since FY2023) , GAAP net income of $41.3M, operating cash flow of -$48.9M, and free cash flow of -$58.5M (-75.3% YoY). On the balance sheet, SRTA closed FY2025 with $325.5M in total assets against $0 in total debt (Altman Z-Score: 5.58, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$197.1M	$41.3M	-$48.9M	-$58.5M	$325.5M	—
FY2024 (FY)	2024-12-31	$146.8M	-$27.3M	-$2.5M	-$33.4M	$256.7M	—
FY2023 (FY)	2023-12-31	$225.2M	-$56.1M	-$32.3M	-$32.3M	—	—

3. SRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Strata Critical Medical Inc. (Class A) (NASDAQ: SRTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.75 (-0.21% 1D, market cap $420.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, SRTA ranks #410 in composite RQD confidence.

How does SRTA compare to AUNA and SBC in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), SRTA carries a Roarable D (47/100 RQD), trailing P/E of 10.2x, gross margin of 20.9%, and ROIC of -7.1%. By comparison, AUNA (Auna SA (Class A)) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $355.3M) and SBC (SBC Medical Group Holdings Incorporated) posts a B- grade (71/100 RQD, P/E 11.5x, ROIC 63.1%, cap $585.2M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRTA?

Per SRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779128), Strata Critical Medical Inc. (Class A) generated $197.1M in revenue (+34.3% YoY), $41.3M in net income, and -$58.5M in free cash flow against $325.5M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

SRTA last traded at $4.75 (-0.21% on volume of 1,246,553 shares), positioning the stock -6.86% below its 50-day simple moving average ($5.10) and -6.86% below its 200-day simple moving average ($5.10). Across its 52-week range of $3.95 to $6.50, SRTA sits at the 31.4% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($4.38 to $5.12).

SRTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SRTA pay a dividend and is it safe?

Strata Critical Medical Inc. (Class A) (SRTA) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SRTA RQD Cockpit SRTA 12M Forecast SRTA Earnings & Move SRTA Dividends & DRIP SRTA Insiders & 13F SRTA Whale Options SRTA Profit Sankey SRTA News & Why